Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-4 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranasal, Inhalation
01
Overview
Interleukin-4 small interfering RNA is an experimental **small interfering RNA** therapeutic designed to silence **interleukin-4** messenger RNA and thereby reduce IL-4 expression. In the cited preclinical literature, it was studied as a locally delivered RNA interference approach to suppress Th2-driven airway inflammation, including virus-induced asthma exacerbation models and allergic airway disease models. The available context supports it as a research-stage, noncommercialized sequence-specific IL-4 gene-silencing agent rather than a uniquely branded clinical drug product, with development centered on academic preclinical evaluation for inflammatory airway diseases such as asthma and allergic rhinitis.
- Other names
- interleukin-4 small interfering ribonucleic acidinterleukin4 small interfering ribonucleic acidinterleukin 4 small interfering ribonucleic acidIL-4 siRNAIL4 siRNAIL 4 siRNAsmall interfering RNA targeted to interleukin-4
02
Targets
IL-4 (Interleukin 4)
Beyond the preview
Go deeper on interleukin-4 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-4 small interfering RNA.